Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies - Schedule of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share (Parenthetical) (Details)

v3.21.2
Summary of Significant Accounting Policies - Schedule of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share (Parenthetical) (Details) - shares
Sep. 30, 2021
Sep. 30, 2020
Anti-dilutive securities    
Warrant issued to purchase common stock 2,117,094 2,118,094
Private Placement    
Anti-dilutive securities    
Warrant issued to purchase common stock 2,828,125  
Loan Agreement    
Anti-dilutive securities    
Warrant issued to purchase common stock 27,548 27,548
Second Draw on Loan Agreement    
Anti-dilutive securities    
Warrant issued to purchase common stock 17,389